Keryx Biopharmaceuticals Moves Third Quarter 2017 Financial Results Call to Tuesday, November 7, 2017 at 8:00 a.m. ET
November 06 2017 - 4:31PM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative medicines to people with
kidney disease, today announced that the company is moving its
conference call that was scheduled for 5:00 p.m. ET today to 8:00
a.m. ET tomorrow morning. The company’s Prescription Drug User Fee
Act (PDUFA) target action date for its supplemental new drug
application for Auryxia is today, November 6, 2017. As of the time
of this press release, the company has not received a response from
the FDA. As such, Keryx has decided to move its third quarter
financial results call to tomorrow.
To participate in the conference call, please
dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and
refer to conference ID: 2193619. The call will be webcast live and
accessible through the Investors section of the company’s website
at www.keryx.com for a period of 15 days after the call.
About Keryx Biopharmaceuticals,
Inc.Keryx Biopharmaceuticals, Inc., with headquarters in
Boston, Massachusetts, is focused on the development and
commercialization of innovative medicines that provide unique and
meaningful advantages to people with kidney disease. The Keryx team
consists of approximately 200 committed people working with passion
to advance the care of people with this complex disease. In
September 2014, the U.S. Food and Drug Administration approved
Keryx’s first medicine, Auryxia® (ferric citrate) tablets. For more
information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contacts:
Amy SullivanSVP, Corporate AffairsT:
617-466-3519Amy.sullivan@keryx.com
Lora PikeSenior Director, Investor Relations & Corporate
CommunicationsT: 617.466.3511lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024